Equities Analysts Set Expectations for RAPT FY2026 Earnings

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Stock analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for RAPT Therapeutics in a note issued to investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.91) for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.14) per share.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69).

RAPT has been the topic of several other reports. Stifel Nicolaus restated a “hold” rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Wells Fargo & Company lowered their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, RAPT Therapeutics currently has an average rating of “Hold” and an average target price of $5.29.

RAPT Therapeutics Trading Up 6.5 %

Shares of NASDAQ:RAPT opened at $1.14 on Tuesday. The firm’s 50 day moving average is $1.23 and its two-hundred day moving average is $1.53. The firm has a market capitalization of $39.85 million, a P/E ratio of -0.41 and a beta of -0.31. RAPT Therapeutics has a 52 week low of $0.79 and a 52 week high of $9.65.

Institutional Trading of RAPT Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RAPT. Barclays PLC grew its holdings in RAPT Therapeutics by 277.2% during the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares during the period. SG Americas Securities LLC boosted its position in shares of RAPT Therapeutics by 401.9% during the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after purchasing an additional 42,636 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in shares of RAPT Therapeutics by 138.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock worth $405,000 after purchasing an additional 116,853 shares during the last quarter. Medicxi Ventures Management Jersey Ltd bought a new stake in shares of RAPT Therapeutics in the 4th quarter worth approximately $35,316,000. Finally, Readystate Asset Management LP acquired a new stake in RAPT Therapeutics during the third quarter valued at approximately $36,000. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.